JP2022123139A - Minoxidil-containing external composition - Google Patents
Minoxidil-containing external composition Download PDFInfo
- Publication number
- JP2022123139A JP2022123139A JP2022101893A JP2022101893A JP2022123139A JP 2022123139 A JP2022123139 A JP 2022123139A JP 2022101893 A JP2022101893 A JP 2022101893A JP 2022101893 A JP2022101893 A JP 2022101893A JP 2022123139 A JP2022123139 A JP 2022123139A
- Authority
- JP
- Japan
- Prior art keywords
- minoxidil
- composition
- water
- tartaric acid
- dibutylhydroxytoluene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 229960003632 minoxidil Drugs 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000002904 solvent Substances 0.000 claims abstract description 15
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000011975 tartaric acid Substances 0.000 claims abstract description 14
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 14
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 12
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 10
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 230000000699 topical effect Effects 0.000 claims description 13
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims description 6
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 6
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 6
- 229940042585 tocopherol acetate Drugs 0.000 claims description 6
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 5
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 5
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 5
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 5
- 239000013078 crystal Substances 0.000 abstract description 15
- 238000004040 coloring Methods 0.000 abstract description 5
- 230000008021 deposition Effects 0.000 abstract 1
- 230000002123 temporal effect Effects 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 description 13
- 235000006708 antioxidants Nutrition 0.000 description 10
- 229960001367 tartaric acid Drugs 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 2
- 229950003631 carpronium chloride Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YHMYGUUIMTVXNW-UHFFFAOYSA-N 1,3-dihydrobenzimidazole-2-thione Chemical compound C1=CC=C2NC(S)=NC2=C1 YHMYGUUIMTVXNW-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000147041 Guaiacum officinale Species 0.000 description 1
- 239000002310 Isopropyl citrate Substances 0.000 description 1
- XBLJCYOUYPSETL-UHFFFAOYSA-N Isopropyl citrate Chemical compound CC(C)O.CC(=O)CC(O)(C(O)=O)CC(O)=O XBLJCYOUYPSETL-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- YYVFXSYQSOZCOQ-UHFFFAOYSA-N Oxyquinoline sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C[NH+]=C2C(O)=CC=CC2=C1.C1=C[NH+]=C2C(O)=CC=CC2=C1 YYVFXSYQSOZCOQ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000019480 chamomile oil Nutrition 0.000 description 1
- 239000010628 chamomile oil Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- VZFDRQUWHOVFCA-UHFFFAOYSA-L disodium;2-sulfanylbutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S)C([O-])=O VZFDRQUWHOVFCA-UHFFFAOYSA-L 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940091561 guaiac Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 229940035429 isobutyl alcohol Drugs 0.000 description 1
- 235000019300 isopropyl citrate Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000003915 liquefied petroleum gas Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960001257 oxyquinoline sulfate Drugs 0.000 description 1
- DOIRQSBPFJWKBE-UHFFFAOYSA-N phthalic acid di-n-butyl ester Natural products CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- -1 preferably ethanol Chemical class 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、ミノキシジルを有効成分として含有する外用組成物に関する。 The present invention relates to a topical composition containing minoxidil as an active ingredient.
ミノキシジル「６－（１－ピペリジニル）－２，４－ピリミジンジアミン－３－オキサイド」は、外用液としての使用により優れた育毛、養毛効果を発揮するため、脱毛症の改善薬として広く使用されている。
一方で、ミノキシジルを含む液剤は経時的に着色して商品価値が低下する、という問題を有している。また、ミノキシジル自体も水やエタノールへの溶解性が悪く、特に低温で保存すると結晶が析出し易い、という問題を有している。
Minoxidil "6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide" is widely used as a remedy for alopecia because it exhibits excellent hair growth and nourishing effects when used as an external solution. ing.
On the other hand, liquid preparations containing minoxidil have the problem that they become colored over time and lose their commercial value. In addition, minoxidil itself has a problem that it has poor solubility in water and ethanol, and crystals tend to precipitate especially when stored at a low temperature.
ミノキシジル含有液剤の経時的な着色を抑制する試みとして、特許文献１や２では特定の抗酸化剤を配合しかつ特定のｐＨ調整剤を使用してｐＨを５．５～７．０の範囲の中で調整しこの問題を解決しようとしている。さらに、特許文献３では、特許文献１や２の技術ではミノキシジル含有液剤の着色を実用上十分に抑制できないとして、有効成分としてのミノキシジルや、溶媒としてのプロピレングリコール、水および低級アルコールの含有量を調整し、経時的な着色の問題と結晶析出の問題との両方を解決しようとしている。 As an attempt to suppress the coloration of minoxidil-containing liquid preparations over time, Patent Documents 1 and 2 contain a specific antioxidant and a specific pH adjuster to adjust the pH to within the range of 5.5 to 7.0. We are trying to fix this problem by adjusting inside. Furthermore, Patent Document 3 states that the techniques of Patent Documents 1 and 2 cannot sufficiently suppress the coloring of minoxidil-containing liquid preparations in practice, and the content of minoxidil as an active ingredient, propylene glycol as a solvent, water and lower alcohol is We are trying to adjust and solve both the problem of coloration over time and the problem of crystal precipitation.
しかしながら、特許文献１、２及び３の技術を含め、現状では、ミノキシジル含有液剤の経時的な着色や結晶析出の問題は未だ十分解決するには至っておらず、これらの問題を確実に解決するミノキシジル含有外用組成物が求められている。
本発明の主な目的は、経時的な着色や結晶析出を確実に抑制、防止することができるミノキシジル含有外用組成物を提供することにある。
However, at present, including the techniques of Patent Documents 1, 2 and 3, the problems of coloration and crystal precipitation of minoxidil-containing liquid preparations over time have not yet been fully resolved. There is a need for topical compositions containing
A main object of the present invention is to provide a minoxidil-containing composition for external use that can reliably suppress or prevent coloration and crystal precipitation over time.
上記課題を解決するため本発明の一態様によれば、
＜１＞ 有効成分としてのミノキシジルと、
溶媒としての水と、
抗酸化剤としてのジブチルヒドロキシトルエンと、
ｐＨ調整剤としての酒石酸とを含有し、ｐＨが６．０～６．５であることを特徴とするミノキシジル含有外用組成物が提供される。
本発明の他の態様としては、例えば、以下のものなどが挙げられる。
＜２＞ 溶媒としてエタノールを更に含有する前記＜１＞に記載のミノキシジル含有外用組成物である。
＜３＞ 溶媒としてプロピレングリコールを更に含有する前記＜２＞に記載のミノキシジル含有外用組成物である。
＜４＞ ミノキシジル含有外用組成物１００ｍＬに対し、ミノキシジル５ｇ、水２０ｇ、ジブチルヒドロキシトルエン０．５ｇを配合した前記＜１＞から＜３＞のいずれかに記載のミノキシジル含有外用組成物である。
In order to solve the above problems, according to one aspect of the present invention,
<1> minoxidil as an active ingredient,
water as a solvent;
dibutyl hydroxytoluene as an antioxidant;
Provided is a minoxidil-containing composition for external use, which contains tartaric acid as a pH adjuster and has a pH of 6.0 to 6.5.
Other aspects of the present invention include, for example, the following.
<2> The minoxidil-containing composition for external use according to <1>, further containing ethanol as a solvent.
<3> The minoxidil-containing topical composition according to <2>, further containing propylene glycol as a solvent.
<4> The minoxidil-containing topical composition according to any one of <1> to <3>, wherein 5 g of minoxidil, 20 g of water, and 0.5 g of dibutylhydroxytoluene are added to 100 mL of the minoxidil-containing topical composition.
本発明は、従来のミノキシジル含有外用組成物に比べ、経時的な着色や結晶析出を確実に抑制、防止することができるものである。 INDUSTRIAL APPLICABILITY The present invention can reliably suppress and prevent coloration and crystal precipitation over time, as compared with conventional minoxidil-containing compositions for external use.
［ミノキシジル含有外用組成物］
本発明のミノキシジル含有外用組成物は主に、有効成分、溶媒、抗酸化剤およびｐＨ調整剤を含有しており、ｐＨが６．０～６．５である。
（１）有効成分
有効成分は主にはミノキシジルである。
ミノキシジルは市販されており、市販のものを使用すればよい。
ミノキシジルの含有量は組成物１００ｍＬに対し通常１～１５ｇであり、中でも好ましくは５ｇである。
有効成分としては、ミノキシジル単独あるいは同薬剤に加えて、ｌ－メントール、ピリドキシン塩酸塩、トコフェロール酢酸エステル、パントテニルエチルエーテルや更には塩化カルプロニウムのなかから選択される少なくとも１種が使用されてもよい。これら追加の薬剤は、それぞれ単独でミノキシジルに添加して使用されてもよいし、２種以上が組み合わされ使用されてもよい。好ましくはミノキシジルに加えｌ－メントール、ピリドキシン塩酸塩、トコフェロール酢酸エステルを組み合わせて、或いはｌ－メントール、トコフェロール酢酸エステル、パントテニルエチルエーテルを組み合わせて使用すればよい。
ミノキシジル以外の有効成分の配合量については、適量を配合すればよく、ｌ－メントールについては組成物１００ｍＬ中０．３ｇ程度、トコフェロール酢酸エステルについては組成物１００ｍＬ中０．０８ｇ程度、ピリドキシン塩酸塩については組成物１００ｍＬ中０．０５ｇ程度、パントテニルエチルエーテルについては組成物１００ｍＬ中１．０ｇ程度、塩化カルプロニウムについては組成物１００ｍＬ中１．０ｇ程度配合すればよい。
[Composition for external use containing minoxidil]
The topical composition containing minoxidil of the present invention mainly contains an active ingredient, a solvent, an antioxidant and a pH adjuster, and has a pH of 6.0 to 6.5.
(1) Active ingredient The active ingredient is mainly minoxidil.
Minoxidil is commercially available, and commercially available products may be used.
The content of minoxidil is usually 1 to 15 g, preferably 5 g, per 100 mL of the composition.
As active ingredients, minoxidil alone or in addition to minoxidil, at least one selected from l-menthol, pyridoxine hydrochloride, tocopherol acetate, pantothenyl ethyl ether, and carpronium chloride may be used. . Each of these additional drugs may be added to minoxidil alone and used, or two or more of them may be used in combination. Preferably, in addition to minoxidil, l-menthol, pyridoxine hydrochloride and tocopherol acetate may be used in combination, or l-menthol, tocopherol acetate and pantothenyl ethyl ether may be used in combination.
Regarding the amount of active ingredients other than minoxidil to be blended, an appropriate amount may be blended, and about 0.3 g in 100 mL of the composition for l-menthol, about 0.08 g in 100 mL for tocopherol acetate, and about 0.08 g in 100 mL of the composition for pyridoxine hydrochloride. is about 0.05 g per 100 mL of the composition, pantothenyl ethyl ether is about 1.0 g per 100 mL of the composition, and carpronium chloride is about 1.0 g per 100 mL of the composition.
（２）溶媒
溶媒には水が含まれる。水の含有量は、主成分であるミノキシジルの配合量に応じて適宜増減すればよい。同組成物１００ｍＬ中にミノキシジルを５ｇ程度まで配合した場合には、水は５～２０ｇ程度配合すればよく、特にミノキシジル５ｇ配合の場合には水を２０ｇ配合することが好ましい。
溶媒としては、水に加えて、プロピレングリコールまた低級アルコールのなかから選択される少なくとも１種が使用されてもよい。これら水以外の２種の溶媒は１種単独で使用されてもよいし、２種が組み合わされ使用されてもよく、好ましくは水に加え前記２種の溶媒を使用されるのがよい。
プロピレングリコールの含有量は、通常、組成物１００ｍＬに対し５～３０ｇであり、好ましくは１０～２０ｇであり、より好ましくは１０～１５ｇである。
低級アルコールとしては、メタノール、エタノール、プロパノール、イソプロピルアルコール、ブタノール、イソブチルアルコール、第二級－ブチルアルコール、第三級－ブチルアルコールなどの炭素数１～４の低級アルコールがあげられる。これら低級アルコールは１種単独で使用されてもよく、２種以上が組み合わされ使用されてもよい。低級アルコールとしては、好ましくはエタノールである。
低級アルコール、中でも好ましいエタノールの含有量は、通常適量であり、本実施形態では組成物の質量又は容量の調整やｐＨ調整剤の溶媒などに使用され、主成分やｐＨ調整剤の配合量に応じて適宜増減すればよい。
(2) Solvent Water is included in the solvent. The content of water may be appropriately increased or decreased according to the blending amount of minoxidil, which is the main component. When about 5 g of minoxidil is blended in 100 mL of the same composition, about 5 to 20 g of water may be blended, and particularly when 5 g of minoxidil is blended, 20 g of water is preferably blended.
As the solvent, in addition to water, at least one selected from propylene glycol and lower alcohols may be used. These two solvents other than water may be used alone, or two may be used in combination. Preferably, the two solvents are used in addition to water.
The content of propylene glycol is usually 5-30 g, preferably 10-20 g, more preferably 10-15 g, per 100 mL of the composition.
Lower alcohols include lower alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropyl alcohol, butanol, isobutyl alcohol, secondary-butyl alcohol and tertiary-butyl alcohol. These lower alcohols may be used singly or in combination of two or more. Ethanol is preferred as the lower alcohol.
The content of lower alcohols, particularly preferably ethanol, is usually an appropriate amount. can be increased or decreased as appropriate.
（３）抗酸化剤
抗酸化剤としては、通常使用されるジブチルヒドロキシトルエン、ブチルヒドロキシアニソール、エリソルビン酸、ＥＤＴＡ－２Ｎａ、クエン酸イソプロピル、没食子酸プロピル、グアヤク酸、アルファチオグリセリン、ジクロルイソシアヌール酸カリウム、２，６－ジ－ｔ－ブチル－４－メチルフェノール、大豆レシチン、チオグリコール酸ナトリウム、チオリンゴ酸ナトリウム、パルミチン酸アスコルビル、２－メルカプトベンズイミダゾール、硫酸オキシキノリン等の中で、本発明の目的及び効果を達成する上では、ジブチルヒドロキシトルエンが好ましい。
ジブチルヒドロキシトルエンの配合量は、組成物１００ｍＬに対し通常０．０１～５ｇであり、好ましくは０．０１～１ｇであり、より好ましくは０．１～１ｇである。
(3) Antioxidants Antioxidants include commonly used dibutylhydroxytoluene, butylhydroxyanisole, erythorbic acid, EDTA-2Na, isopropyl citrate, propyl gallate, guaiac acid, alphathioglycerin, and dichloroisocyanur. Potassium acid, 2,6-di-t-butyl-4-methylphenol, soybean lecithin, sodium thioglycolate, sodium thiomalate, ascorbyl palmitate, 2-mercaptobenzimidazole, oxyquinoline sulfate and the like. Dibutylhydroxytoluene is preferred in order to achieve the object and effect of .
The amount of dibutylhydroxytoluene compounded is usually 0.01 to 5 g, preferably 0.01 to 1 g, more preferably 0.1 to 1 g per 100 mL of the composition.
（４）ｐＨ調整剤
ｐＨ調整剤としては、通常使用されるクエン酸、乳酸、塩酸、リン酸、硫酸、リンゴ酸、リンゴ酸ナトリウム、コハク酸、コハク酸ナトリウム、酒石酸、酒石酸ナトリウム等の中で、本発明の目的及び効果を達成する上では、酒石酸の使用が好ましい。また、酒石酸を用いることで、組成物の製造時における機器の腐食や、組成物における不快な刺激臭の発生を抑制することもできる。酒石酸の使用量は、使用する薬剤や目的とするｐＨ値に応じて決定すればよく、組成物１００ｍＬにおいて０．１～０．５ｇ使用して目的とする領域のｐＨとすればよい。
(4) pH adjuster As a pH adjuster, among commonly used citric acid, lactic acid, hydrochloric acid, phosphoric acid, sulfuric acid, malic acid, sodium malate, succinic acid, sodium succinate, tartaric acid, sodium tartrate, etc. , the use of tartaric acid is preferred for achieving the objects and effects of the present invention. Further, by using tartaric acid, it is possible to suppress the corrosion of equipment during the production of the composition and the generation of an unpleasant irritating odor in the composition. The amount of tartaric acid to be used may be determined according to the drug to be used and the desired pH value.
（５）その他添加剤
本発明のミノキシジル含有外用組成物には、薬学的または生理学的に許容される医薬外用剤、医薬部外品、化粧品用の添加剤が含有されてもよい。添加剤としては、目的とする製剤の剤型に応じて適宜選択、使用すればよく、具体的には界面活性剤、増粘剤、保存剤、安定化剤、刺激軽減剤、防腐剤、着色剤、香料、溶解補助剤などがあげられる。より具体的には、カミツレ油、セタノール、ヒアルロン酸ナトリウムをあげることができる。これら添加剤は１種単独で使用されてもよいし、２種以上が組み合わされ使用されてもよい。また、後述のエアゾール剤とする場合は、液化石油ガス、ジメチルエーテルを噴射剤として添加して使用すればよい。これらの添加剤の使用量は、特に制限されず、目的の剤型に応じて、使用量も選択すればよい。
(5) Other Additives The minoxidil-containing topical composition of the present invention may contain pharmaceutically or physiologically acceptable external drugs, quasi-drugs, and cosmetic additives. Additives may be appropriately selected and used according to the dosage form of the desired formulation. Specifically, surfactants, thickeners, preservatives, stabilizers, irritation reducing agents, preservatives, and coloring agents may be used. agents, fragrances, solubilizers, and the like. More specific examples include chamomile oil, cetanol, and sodium hyaluronate. These additives may be used singly or in combination of two or more. In the case of an aerosol agent, which will be described later, liquefied petroleum gas or dimethyl ether may be added as a propellant. The amount of these additives to be used is not particularly limited, and the amount to be used may be selected according to the desired dosage form.
［ミノキシジル含有外用組成物の製造方法］
本発明の好ましい実施形態にかかるミノキシジル含有外用組成物は、以下に例示する剤型に応じた通常の外用組成物の製造方法を使用すればよく、具体的には、エタノール、水、プロピレングリコールといった液状成分にミノキシジルや他の成分を添加、混合或いは必要に応じて溶解し、酒石酸でｐＨを調整して製造すればよい。
[Method for producing minoxidil-containing topical composition]
The minoxidil-containing composition for external use according to a preferred embodiment of the present invention may be produced by a normal method for producing a composition for external use according to the dosage form illustrated below. Specifically, ethanol, water, propylene glycol, etc. Minoxidil and other ingredients may be added to, mixed with, or dissolved as necessary in the liquid component, and pH may be adjusted with tartaric acid for production.
［剤型］
本発明の好ましい実施形態にかかるミノキシジル含有外用組成物の形態は特に限定されず、液剤、乳剤、クリーム剤、ゲル剤、リニメント剤、ローション剤、エアゾール剤などの形態で使用すればよい。これら形態のなかでも、液剤、乳剤、ローション剤、エアゾール剤の形態で使用するのが好ましく、ローション剤等の液剤、液剤に噴霧ガスを組み合わせたエアゾール剤の形態での使用が一般的である。
[Dosage form]
The form of the minoxidil-containing topical composition according to the preferred embodiment of the present invention is not particularly limited, and may be used in the form of liquid, emulsion, cream, gel, liniment, lotion, aerosol, and the like. Among these forms, liquid formulations, emulsion formulations, lotions, and aerosol formulations are preferred, and liquid formulations such as lotions and aerosol formulations in which a spray gas is combined with liquid formulations are generally used.
［用法・用量］
本発明のミノキシジル含有外用組成物の使用方法は、使用対象の毛髪の状態、頭皮の状態、年齢、性別などによって異なるが、一般的には以下のようにすればよい。
すなわち、１日数回（たとえば、約１～５回、好ましくは１～３回）、適量（たとえば、約０．５～２ｇまたは０．５～２ｍＬ）を皮膚（たとえば、頭皮）に適用すればよい。発毛、育毛の効果をより具体的に達成するには、ミノキシジルの１日使用量が、たとえば約１～１，０００ｍｇとなるように組成物を頭皮に適用すればよい。
適用方法は、剤型に合わせて、塗布、または噴霧等すればよい。
使用期間は、通常７日間以上であり、育毛効果が十分に得られるまで使用すればよい。
[Dosage and administration]
The method of using the minoxidil-containing composition for external use of the present invention varies depending on the condition of the hair, scalp, age, sex, etc. of the subject, but generally the method may be as follows.
That is, if an appropriate amount (eg, about 0.5-2 g or 0.5-2 mL) is applied to the skin (eg, scalp) several times a day (eg, about 1 to 5 times, preferably 1 to 3 times) good. In order to more specifically achieve the effects of hair growth and restoration, the composition may be applied to the scalp such that the daily dose of minoxidil is, for example, about 1 to 1,000 mg.
The application method may be coating or spraying depending on the dosage form.
The period of use is usually 7 days or longer, and may be used until a sufficient hair growth effect is obtained.
以上の本発明のミノキシジル含有外用組成物によれば、溶媒として水、抗酸化剤としてのジブチルヒドロキシトルエンの使用と酒石酸によるｐＨの最適範囲への調整により、経時的な着色や結晶析出をより確実に抑制、防止することができる。 According to the minoxidil-containing topical composition of the present invention, the use of water as a solvent, dibutylhydroxytoluene as an antioxidant, and adjustment of the pH to the optimum range with tartaric acid ensures that coloration and crystal precipitation occur over time. can be suppressed and prevented.
以下、本発明を実施例により更に詳細に説明するが、本発明はこれら実施例により限定されるものではない。 EXAMPLES The present invention will be described in more detail below with reference to Examples, but the present invention is not limited to these Examples.
（１）サンプルの調製
外用液剤の常法の調製法に従い表１～３の組成のミノキシジル含有組成物サンプルを調製した。即ち、エタノールと水、プロピレングリコールにミノキシジルや他の成分を溶解させ、最後に酒石酸でｐＨを調整し、ミノキシジル含有組成物のサンプルを製造した。
(1) Preparation of Sample Minoxidil-containing composition samples having the compositions shown in Tables 1 to 3 were prepared according to the conventional preparation method for external preparations. That is, minoxidil and other ingredients were dissolved in ethanol, water, and propylene glycol, and finally the pH was adjusted with tartaric acid to prepare samples of minoxidil-containing compositions.
（２）サンプルの評価
結晶析出がないことおよび経時着色がないことを示す実験データを比較例１～８のサンプルと共に表１～３に示す。
・「溶解性・結晶析出・着色の評価」
後掲の表１～３に示す組成に従い、各成分を混合溶解し、全量を１００ｍＬとした。調製した実施例及び比較例のサンプルを２０ｍＬのガラス容器に充填した。
溶解性の評価は、各組成物を調製時に、目視で溶解しやすいかどうかを観察することによって行った。容易に溶解するものを○、溶解しにくいものを△、非常に溶解しにくいものを×とした。
低温安定性の評価は、各組成物を４℃の恒温器で約３ヶ月静置したのち、目視で確認した。結晶の析出が認められなかったものを○、認められたものを×とした。
熱安定性の評価は、各組成物を４０℃の恒温槽で約３ヶ月静置したのち、目視で褐変の程度を確認することにより行った。着色が認められない場合を－、わずかな着色が認められた場合を＋、着色がより強く認められるごとに＋の数を増やして表示した。
(2) Sample Evaluation Tables 1-3 show experimental data showing no crystal precipitation and no coloration over time, together with the samples of Comparative Examples 1-8.
・Evaluation of solubility, crystal precipitation, and coloration
Each component was mixed and dissolved according to the compositions shown in Tables 1 to 3 below, and the total amount was adjusted to 100 mL. The prepared samples of Examples and Comparative Examples were filled in 20 mL glass containers.
Solubility evaluation was performed by visually observing whether each composition was easy to dissolve at the time of preparation. Those that were easily dissolved were evaluated as ◯, those that were difficult to dissolve were evaluated as Δ, and those that were extremely difficult to dissolve were evaluated as ×.
In the evaluation of low-temperature stability, each composition was allowed to stand in a thermostat at 4°C for about 3 months, and then visually confirmed. A case where crystal precipitation was not observed was evaluated as ◯, and a case where crystal precipitation was observed was evaluated as X.
Thermal stability was evaluated by allowing each composition to stand in a constant temperature bath at 40° C. for about 3 months, and then visually checking the degree of browning. - indicates that no coloring is observed, + indicates that slight coloring is observed, and the number of + is increased as the coloring is more strongly observed.
表１に示すように、ｐＨが６．０～６．５の範囲で、溶解性、熱安定性、低温安定性で問題はなかった。これに対して、組成物のｐＨが６．０未満の場合、低温での結晶析出が認められ、６．５を超える場合、溶解性が低下し、低温での結晶析出および熱による着色が認められた。 As shown in Table 1, there were no problems in solubility, thermal stability, and low-temperature stability within the pH range of 6.0 to 6.5. On the other hand, when the pH of the composition is less than 6.0, crystal precipitation at low temperature is observed, and when it exceeds 6.5, the solubility is reduced, crystal precipitation at low temperature and coloration due to heat are observed. was taken.
表２に示すように、抗酸化剤がジブチルヒドロキシトルエンの場合は、溶解性、熱安定性、低温安定性ともに問題はなかった。しかし、抗酸化剤を亜硫酸水素ナトリウム、アスコルビン酸に変えた場合および抗酸化剤を加えなかった場合は、熱安定性に難があり着色した。 As shown in Table 2, when the antioxidant was dibutylhydroxytoluene, there were no problems with solubility, thermal stability, or low-temperature stability. However, when the antioxidant was changed to sodium hydrogen sulfite or ascorbic acid, or when no antioxidant was added, heat stability was poor and coloration occurred.
表３に示すように、ｐＨ調整剤をクエン酸、乳酸にした場合は熱安定性に難があり、着色した。一方、酒石酸を用いたサンプルではいずれも溶解性、熱安定性、低温安定性に問題なかった。 As shown in Table 3, when citric acid or lactic acid was used as the pH adjuster, heat stability was poor, resulting in coloration. On the other hand, the samples using tartaric acid had no problems with solubility, thermal stability, and low-temperature stability.
（３）まとめ
表１～３に示すとおり、実施例サンプルは、比較例サンプルに比べ結晶析出や経時着色の抑制、防止に効果に優れている。以上から、抗酸化剤としてジブチルヒドロキシトルエンを使用し、溶媒としての水を使用し、酒石酸を用いてｐＨを最適範囲に調整することが、結晶析出や経時着色の抑制、防止に有用であることが明らかとなった。
(3) Summary As shown in Tables 1 to 3, the example samples are more effective in suppressing and preventing crystal precipitation and coloration over time than the comparative example samples. From the above, using dibutylhydroxytoluene as an antioxidant, using water as a solvent, and adjusting the pH to an optimum range using tartaric acid is useful for suppressing and preventing crystal precipitation and coloration over time. became clear.
Claims (4)
溶媒としての水、プロピレングリコール、及びエタノールからなる組合せと、
抗酸化剤としてのジブチルヒドロキシトルエンと、
ｐＨ調整剤としての酒石酸とを含有し、
ｐＨが６．０～６．５であるミノキシジル含有外用組成物であって、
ミノキシジル含有外用組成物１００ｍＬに対し、ミノキシジル５ｇ、ｌ－メントール０．３ｇ、ピリドキシン塩酸塩０．０５ｇ、トコフェロール酢酸エステル０．０８ｇ、水５～２０ｇ、プロピレングリコール１０～１５ｇ、ジブチルヒドロキシトルエン０．１～０．５ｇ、酒石酸０．１～０．５ｇを配合したことを特徴とするミノキシジル含有外用組成物。 a combination consisting of minoxidil, l-menthol, pyridoxine hydrochloride and tocopherol acetate as active ingredients;
a combination consisting of water, propylene glycol, and ethanol as solvents;
dibutyl hydroxytoluene as an antioxidant;
Contains tartaric acid as a pH adjuster,
A minoxidil-containing topical composition having a pH of 6.0 to 6.5,
Minoxidil 5 g, l-menthol 0.3 g, pyridoxine hydrochloride 0.05 g, tocopherol acetate 0.08 g, water 5 to 20 g, propylene glycol 10 to 15 g, dibutylhydroxytoluene 0.1 per 100 mL of minoxidil-containing topical composition 0.5 g of minoxidil and 0.1 to 0.5 g of tartaric acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022101893A JP7304463B2 (en) | 2018-01-29 | 2022-06-24 | Topical composition containing minoxidil |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018012175A JP2019131474A (en) | 2018-01-29 | 2018-01-29 | Minoxidil-containing external composition |
| JP2022101893A JP7304463B2 (en) | 2018-01-29 | 2022-06-24 | Topical composition containing minoxidil |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018012175A Division JP2019131474A (en) | 2018-01-29 | 2018-01-29 | Minoxidil-containing external composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022123139A true JP2022123139A (en) | 2022-08-23 |
| JP7304463B2 JP7304463B2 (en) | 2023-07-06 |
Family
ID=86996461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022101893A Active JP7304463B2 (en) | 2018-01-29 | 2022-06-24 | Topical composition containing minoxidil |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7304463B2 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001288090A (en) * | 2000-04-07 | 2001-10-16 | Taisho Pharmaceut Co Ltd | Minoxidil-containing pharmaceutical preparation |
| JP2002308740A (en) * | 2001-04-05 | 2002-10-23 | Taisho Pharmaceut Co Ltd | Minoxidil-containing preparation |
| JP2014214098A (en) * | 2013-04-24 | 2014-11-17 | ロート製薬株式会社 | Composition for external application containing minoxidil |
| JP2014214097A (en) * | 2013-04-24 | 2014-11-17 | ロート製薬株式会社 | Composition for external application containing minoxidil |
| JP2016138094A (en) * | 2015-01-23 | 2016-08-04 | 大正製薬株式会社 | External composition |
| JP2017119688A (en) * | 2015-12-29 | 2017-07-06 | 大正製薬株式会社 | External composition |
-
2022
- 2022-06-24 JP JP2022101893A patent/JP7304463B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001288090A (en) * | 2000-04-07 | 2001-10-16 | Taisho Pharmaceut Co Ltd | Minoxidil-containing pharmaceutical preparation |
| JP2002308740A (en) * | 2001-04-05 | 2002-10-23 | Taisho Pharmaceut Co Ltd | Minoxidil-containing preparation |
| JP2014214098A (en) * | 2013-04-24 | 2014-11-17 | ロート製薬株式会社 | Composition for external application containing minoxidil |
| JP2014214097A (en) * | 2013-04-24 | 2014-11-17 | ロート製薬株式会社 | Composition for external application containing minoxidil |
| JP2016138094A (en) * | 2015-01-23 | 2016-08-04 | 大正製薬株式会社 | External composition |
| JP2017119688A (en) * | 2015-12-29 | 2017-07-06 | 大正製薬株式会社 | External composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7304463B2 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6215102B2 (en) | Pharmaceutical composition | |
| KR101409789B1 (en) | Antimycotic pharmaceutical composition | |
| JP5527787B2 (en) | Hair growth composition | |
| JP2016145179A (en) | Minoxidil-containing liquid medicine for external use, and manufacturing method of liquid medicine for external use | |
| JP2016145180A (en) | Liquid medicine for external use, and manufacturing method of liquid medicine for external use | |
| JP2024050998A (en) | Composition for external use containing minoxidil and method for preventing deposition of minoxidil | |
| TWI766912B (en) | Aqueous formulation | |
| JP2023171964A (en) | Composition for external use | |
| JP7304463B2 (en) | Topical composition containing minoxidil | |
| TW202000193A (en) | External-use composition | |
| JP2023099672A (en) | External pharmaceutical composition | |
| JP2019131474A (en) | Minoxidil-containing external composition | |
| JP2006022091A (en) | Composition for growing hair | |
| KR20160029769A (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Hydroxydecanoic acid | |
| JP2008056703A (en) | Composition for hair restoration | |
| JP5558332B2 (en) | Scalp hair cosmetics | |
| KR20150085968A (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Sinomenine Hydrochloride | |
| TWI815914B (en) | External compositions and methods for inhibiting the formation of precipitates | |
| JP2007191473A (en) | New hair-growing composition | |
| JP2021134164A (en) | Hair growth external preparation containing minoxidil and pantothenyl ethyl ether, and methods for stabilizing that pantothenyl ethyl ether and inhibiting crystallization of minoxidil and the like | |
| KR101602468B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Hydroxydecanoic acid | |
| JP7379094B2 (en) | External liquid | |
| JP5565995B2 (en) | Antipruritic | |
| KR102000935B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing 5-hydroxytryptophan | |
| JP2021195323A (en) | External composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220627 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230606 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230626 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7304463 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |